CDK7-IN-2 |
| رقم الكتالوجGC63980 |
CDK7-IN-2 هو مثبط قوي لـ CDK7CDK7 متورط في كل من التحكم الزمني في دورة الخلية ونشاط النسخيتم تضمين CDK7 في عملية بدء النسخ عن طريق الفسفرة للوحدة الفرعية Rbpl من RNA Polymerase II (RNAPII)CDK7 لديه القدرة على البحث عن أمراض السرطان ، وخاصة السرطانات العدوانية والتي يصعب علاجها (مستخرج من براءة الاختراع WO2019099298A1 ، المركب 1)
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2326428-19-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1)[1].
[1]. David Andrew Coates, et al. Compounds useful for inhibiting cdk7. Patent WO2019099298A1.
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *